Physician profile
Amy E Slear
NPI 1356354203
$13,380.75
in general payments reported to CMS, 2019-2025
39 companies · $2,354 in 2025
The $2,354 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,780 · 2020: $933 · 2021: $1,629 · 2022: $1,935 · 2023: $2,273 · 2024: $2,477 · 2025: $2,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,893 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,893.43 |
| Education | $210.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,906.44 | 2019-2025 | |
| Janssen Biotech, INC. | $1,081.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $884.87 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Leo Pharma INC. | $861.74 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $830.00 | 2019-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $732.55 | 2022-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $714.25 | 2023-2025 | Zoryve |
| Amgen INC. | $686.36 | 2019-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $634.61 | 2019-2025 | |
| Almirall LLC | $607.08 | 2019-2025 | Klisyri |
| Galderma Laboratories, L.P. | $536.83 | 2019-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $498.95 | 2019-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $413.15 | 2019-2024 | Siliq, Cabtreo, Duobrii |
| Genzyme Corporation | $382.24 | 2019-2025 | |
| Ucb, INC. | $319.81 | 2021-2025 | Bimzelx, Cimzia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Slear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.